177 related articles for article (PubMed ID: 36819647)
1. A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by
Teigell-Muñoz FJ; Mateos-González M; Bernal Hertfelder E; Sánchez de Torre A; García-Ferrón M; de Cáceres Velasco C; Bueno Muiño C
Eur J Case Rep Intern Med; 2023; 10(1):003654. PubMed ID: 36819647
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
Fazili T; Bansal E; Garner D; Gomez M; Stornelli N
Int J Antimicrob Agents; 2023 Apr; 61(4):106749. PubMed ID: 36758775
[TBL] [Abstract][Full Text] [Related]
3. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.
Gil-Navarro MV; Lopez-Cortes LE; Luque-Marquez R; Galvez-Acebal J; de Alarcon-Gonzalez A
J Clin Pharm Ther; 2018 Apr; 43(2):220-223. PubMed ID: 29030859
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
Sader HS; Mendes RE; Pfaller MA; Flamm RK
J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
[TBL] [Abstract][Full Text] [Related]
5. Use of dalbavancin in infective endocarditis: a case series.
Guleri A; More R; Sharma R; Wong M; Abdelrahman A
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab099. PubMed ID: 34396119
[TBL] [Abstract][Full Text] [Related]
6. Safety and clinical outcomes of outpatient parenteral antibiotic therapy for infective endocarditis in Christchurch, New Zealand: A retrospective cohort study.
Campbell PO; Gallagher K; Dalton SC; Metcalf SCL; Douglas NM; Chambers ST
Int J Infect Dis; 2023 Sep; 134():172-176. PubMed ID: 37331565
[TBL] [Abstract][Full Text] [Related]
7. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci.
Hidalgo-Tenorio C; Sadyrbaeva-Dolgova S; Enríquez-Gómez A; Muñoz P; Plata-Ciezar A; Miró JM; Alarcón A; Martínez-Marcos FJ; Loeches B; Escrihuela-Vidal F; Vinuesa D; Herrero C; Boix-Palop L; Del Mar Arenas M; Vázquez EG; de Las Revillas FA; Pasquau J;
Int J Antimicrob Agents; 2023 Sep; 62(3):106918. PubMed ID: 37442488
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care.
Ajaka L; Heil E; Schmalzle S
Antibiotics (Basel); 2020 Oct; 9(10):. PubMed ID: 33076275
[TBL] [Abstract][Full Text] [Related]
9.
Herrera-Hidalgo L; de Alarcón A; López-Cortes LE; Luque-Márquez R; López-Cortes LF; Gutiérrez-Valencia A; Gil-Navarro MV
Antibiotics (Basel); 2020 Sep; 9(10):. PubMed ID: 33007853
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
[TBL] [Abstract][Full Text] [Related]
11. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
[TBL] [Abstract][Full Text] [Related]
12. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series.
Evins C; Lancaster H; Schnee AE
Ann Clin Microbiol Antimicrob; 2022 Apr; 21(1):16. PubMed ID: 35473711
[TBL] [Abstract][Full Text] [Related]
13. The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs.
Douglass AH; Mayer H; Young K; Sikka MK; Strnad L; Makadia J; Sukerman E; Lewis JS; Streifel AC
Ther Adv Infect Dis; 2023; 10():20499361231189405. PubMed ID: 37581105
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
Aparicio-Minguijón E; Boán J; Terrón A; Heredia C; Puente C; Pérez-Jacoiste Asín A; Orellana MÁ; Domínguez L; Caro JM; López-Gude MJ; Aguilar-Blanco EM; Eixerés-Esteve A; López-Medrano F
Enferm Infecc Microbiol Clin (Engl Ed); 2024 Jun; ():. PubMed ID: 38902152
[TBL] [Abstract][Full Text] [Related]
15. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
[TBL] [Abstract][Full Text] [Related]
16. Treatment of
Herrera-Hidalgo L; Fernández-Rubio B; Luque-Márquez R; López-Cortés LE; Gil-Navarro MV; de Alarcón A
Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107066
[TBL] [Abstract][Full Text] [Related]
17. Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?
Herrera-Hidalgo L; de Alarcón A; López-Cortes LE; Luque-Márquez R; López-Cortes LF; Gutiérrez-Valencia A; Gil-Navarro MV
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046488
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.
Suárez M; Pérez-Landeiro A; Sanjurjo A; Lima O; Sousa A; López A; Martínez-Lamas L; Cabrera X; Rubianes M; Pérez-Rodríguez MT
Int J Infect Dis; 2024 Jan; 138():41-45. PubMed ID: 37931892
[TBL] [Abstract][Full Text] [Related]
19. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
McSorley JC; Reyes D; Tonna I; Bateman V
Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin for infective endocarditis: a single centre experience.
Durante-Mangoni E; Boccia F; Ursi MP; Karruli A; Andini R; Galdo M; Zampino R
J Chemother; 2021 Jul; 33(4):256-262. PubMed ID: 33073724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
